Department of Liver and Gastrointestinal Diseases, Biodonostia Research Institute, Donostia University Hospital, University of the Basque Country (UPV/EHU), San Sebastián, Spain.
Department of Liver and Gastrointestinal Diseases, Biodonostia Research Institute, Donostia University Hospital, University of the Basque Country (UPV/EHU), San Sebastián, Spain; National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, Instituto de Salud Carlos III), Madrid, Spain.
Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4 Pt B):1335-1344. doi: 10.1016/j.bbadis.2017.08.016. Epub 2017 Sep 13.
Cholangiocarcinoma (CCA) is an aggressive tumor type affecting cholangiocytes. CCAs frequently arise under certain cholestatic liver conditions. Intrahepatic accumulation of bile acids may facilitate cocarcinogenic effects by triggering an inflammatory response and cholangiocyte proliferation. Here, the role of bile acid receptors FXR and TGR5 in CCA progression was evaluated.
FXR and TGR5 expression was determined in human CCA tissues and cell lines. An orthotopic model of CCA was established in immunodeficient mice and tumor volume was monitored by magnetic resonance imaging under chronic administration of the specific FXR or TGR5 agonists, obeticholic acid (OCA) or INT-777 (0,03% in chow; Intercept Pharmaceuticals), respectively. Functional effects of FXR or TGR5 activation were evaluated on CCA cells in vitro.
FXR was downregulated whereas TGR5 was upregulated in human CCA tissues compared to surrounding normal liver tissue. FXR expression correlated with tumor differentiation and TGR5 correlated with perineural invasion. TGR5 expression was higher in perihilar than in intrahepatic CCAs. In vitro, FXR was downregulated and TGR5 was upregulated in human CCA cells compared to normal human cholangiocytes. OCA halted CCA growth in vivo, whereas INT-777 showed no effect. In vitro, OCA inhibited CCA cell proliferation and migration which was associated with decreased mitochondrial energy metabolism. INT-777, by contrast, stimulated CCA cell proliferation and migration, linked to increased mitochondrial energy metabolism.
Activation of FXR inhibits, whereas TGR5 activation may promote, CCA progression by regulating proliferation, migration and mitochondrial energy metabolism. Modulation of FXR or TGR5 activities may represent potential therapeutic strategies for CCA.
胆管癌(CCA)是一种侵袭性肿瘤,影响胆管细胞。CCA 常发生于某些胆汁淤积性肝病情况下。胆汁酸在肝内蓄积可能通过触发炎症反应和胆管细胞增殖促进协同致癌作用。本研究旨在评估胆汁酸受体 FXR 和 TGR5 在 CCA 进展中的作用。
检测人 CCA 组织和细胞系中 FXR 和 TGR5 的表达。在免疫缺陷小鼠中建立 CCA 原位模型,在慢性给予 FXR 或 TGR5 特异性激动剂,即奥贝胆酸(OCA)或 INT-777(0.03%在饲料中;Intercept 制药公司)的情况下,通过磁共振成像监测肿瘤体积。在体外评估 FXR 或 TGR5 激活对 CCA 细胞的功能影响。
与周围正常肝组织相比,人 CCA 组织中 FXR 下调而 TGR5 上调。FXR 表达与肿瘤分化相关,TGR5 表达与神经周围浸润相关。肝门部 CCA 的 TGR5 表达高于肝内 CCA。与正常人类胆管细胞相比,人 CCA 细胞中 FXR 下调而 TGR5 上调。在体内,OCA 可阻止 CCA 生长,而 INT-777 无作用。在体外,OCA 抑制 CCA 细胞增殖和迁移,与线粒体能量代谢减少相关。相反,INT-777 刺激 CCA 细胞增殖和迁移,与线粒体能量代谢增加相关。
FXR 激活抑制,而 TGR5 激活可能促进 CCA 进展,通过调节增殖、迁移和线粒体能量代谢。FXR 或 TGR5 活性的调节可能代表 CCA 的潜在治疗策略。